Floatz logo

ag-120

AML Arising From Myelodysplastic Syndrome (MDS)

Institut de Recherches Internationales ServierPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the AML Arising From Myelodysplastic Syndrome (MDS) cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
Daunorubicin
Institut de Recherches Internationales Servier
Phase 3BB
ETOPOSIDE
Institut de Recherches Internationales Servier
Phase 2BB
Decitabine
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
City of Hope Medical Center
Phase 3BB

View all 50 →

Same molecule, other indications

ag-120 is also rated in:

IDH1 MutationDormant
BB
Indicative ·
64 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →